World's Best Scientists 2026 revealed!
Award Badge
Medicine
South Africa
2025

D-Index & Metrics

Medicine

D-Index
124
Citations
107231
World Ranking
3145
National Ranking
131

Alvaro Avezum publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alvaro Avezum sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 449 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alvaro Avezum D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alvaro Avezum sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 124 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Medicine in South Africa Leader Award
  • 2023 - Research.com Medicine in South Africa Leader Award
  • 2022 - Research.com Medicine in South Africa Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Myocardial infarction
  • Surgery

His main research concerns Internal medicine, Myocardial infarction, Stroke, Randomized controlled trial and Surgery. His biological study spans a wide range of topics, including Placebo, Endocrinology and Cardiology. His work deals with themes such as Epidemiology, Heart failure and Emergency medicine, which intersect with Myocardial infarction.

His Stroke research focuses on subjects like Atrial fibrillation, which are linked to Heart rate. His study in Randomized controlled trial is interdisciplinary in nature, drawing from both Anesthesia and Confidence interval. His Surgery study combines topics from a wide range of disciplines, such as Warfarin and Risk factor.

His most cited work include:

  • Apixaban versus Warfarin in Patients with Atrial Fibrillation (5705 citations)
  • Apixaban in Patients with Atrial Fibrillation (1891 citations)
  • Predictors of hospital mortality in the global registry of acute coronary events. (1578 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Internal medicine, Cardiology, Stroke, Myocardial infarction and Epidemiology. His research on Internal medicine frequently connects to adjacent areas such as Surgery. In general Cardiology, his work in ST elevation, Coronary artery disease and Ejection fraction is often linked to In patient linking many areas of study.

As a part of the same scientific family, Alvaro Avezum mostly works in the field of Stroke, focusing on Aspirin and, on occasion, Rivaroxaban. His Myocardial infarction study incorporates themes from Odds ratio and Risk factor. His Epidemiology research is multidisciplinary, relying on both Gerontology, Environmental health, Diabetes mellitus, Disease and Prospective cohort study.

He most often published in these fields:

  • Internal medicine (51.99%)
  • Cardiology (28.48%)
  • Stroke (24.83%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (51.99%)
  • Epidemiology (16.56%)
  • Randomized controlled trial (15.56%)

In recent papers he was focusing on the following fields of study:

Alvaro Avezum mainly focuses on Internal medicine, Epidemiology, Randomized controlled trial, Stroke and Prospective cohort study. The Internal medicine study combines topics in areas such as Placebo and Cardiology. He has researched Epidemiology in several fields, including Diabetes mellitus, Cohort study, Family medicine and Environmental health.

His study in the fields of Clinical endpoint under the domain of Randomized controlled trial overlaps with other disciplines such as Hydroxychloroquine. Alvaro Avezum has included themes like Renal function, Heart failure, Atrial fibrillation and Risk factor in his Stroke study. The various areas that Alvaro Avezum examines in his Prospective cohort study study include Incidence, Blood lipids, Disease, Vascular disease and Cohort.

Between 2018 and 2021, his most popular works were:

  • Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (593 citations)
  • Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. (383 citations)
  • Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. (227 citations)

Best Publications

  • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

    Salim Yusuf;Steven Hawken;Stephanie Ôunpuu;Tony Dans

  • Apixaban versus Warfarin in Patients with Atrial Fibrillation

    Christopher B. Granger;John H. Alexander;Renato D. Lopes;Elaine M. Hylek

  • Apixaban in Patients with Atrial Fibrillation

    Stuart J. Connolly;John Eikelboom;Campbell Joyner;Hans-Christoph Diener

  • Predictors of hospital mortality in the global registry of acute coronary events.

    Christopher B. Granger;Robert J. Goldberg;Omar Dabbous;Karen S. Pieper

  • Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.

    P J Devereaux

  • Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

    Sanjit S Jolly;Salim Yusuf;John Cairns;Kari Niemelä

  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

    John W. Eikelboom;Stuart J. Connolly;Jackie Bosch;Gilles R. Dagenais

  • Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries

    Clara K. Chow;Clara K. Chow;Koon K. Teo;Sumathy Rangarajan;Shofiqul Islam

  • Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study

    Martin J O'Donnell;Martin J O'Donnell;Siu Lim Chin;Sumathy Rangarajan;Denis Xavier

  • A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry

    Kim A Eagle;Michael J Lim;Omar H Dabbous;Karen S Pieper

  • Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

    Keith A A Fox;Omar H Dabbous;Robert J Goldberg;Karen S Pieper

  • Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study

    Salim Yusuf;Philip Joseph;Sumathy Rangarajan;Shofiqul Islam

  • Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study

    Darryl P Leong;Darryl P Leong;Koon K Teo;Koon K Teo;Sumathy Rangarajan;Patricio Lopez-Jaramillo

  • Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

    R. S. McKelvie;S. Yusuf;D. Pericak;A. Avezum

  • Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study

    Mahshid Dehghan;Andrew Mente;Andrew Mente;Xiaohe Zhang;Sumathi Swaminathan

  • The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study

    Scott A Lear;Weihong Hu;Sumathy Rangarajan;Danijela Gasevic

  • Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

    James J Ferguson;Robert M Califf;Elliott M Antman;Marc Cohen

  • Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

    Salim Yusuf;Shofiqul Islam;Clara K Chow;Sumathy Rangarajan

  • Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

    Bruno M Tomazini;Israel S Maia;Alexandre B Cavalcanti;Otavio Berwanger

  • Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.

    Alexandre B. Cavalcanti;Fernando G. Zampieri;Regis G. Rosa;Luciano C.P. Azevedo

Frequent Co-Authors

Salim Yusuf
Salim Yusuf McMaster University
Patricio López-Jaramillo
Patricio López-Jaramillo University of Santander
Rafael Diaz
Rafael Diaz University of Alberta
Koon K. Teo
Koon K. Teo McMaster University
Annika Rosengren
Annika Rosengren Sahlgrenska University Hospital
Gilles R. Dagenais
Gilles R. Dagenais Université Laval
Sumathy Rangarajan
Sumathy Rangarajan Population Health Research Institute
Rajeev Gupta
Rajeev Gupta Rajasthan University of Health Sciences
Keith A.A. Fox
Keith A.A. Fox University of Edinburgh
Renato D. Lopes
Renato D. Lopes Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in healthcare doesn’t always mean attending medical school. There are a variety of online degrees and credentials that can open doors to well-paying roles in the medical field.

For those interested in the administrative side, exploring online medical billing and coding can provide specialized skills to work in healthcare offices, insurance companies, and hospitals.

Nursing remains in high demand, and many accredited programs now offer flexibility to start or advance your nursing education remotely. If you’re aiming to become a nurse, discover what is the cheapest online college for nursing? to maximize affordability and access.

For licensed nurses seeking advanced practice roles, there are options for further specialization. You can compare programs based on cost and value, with practical guides such as the cheapest online acute care nurse practitioner programs.

Ambitious professionals can also pursue terminal degrees without giving up their careers. Several online phd programs nursing are available, providing flexible ways to lead, teach, or conduct research in healthcare.

Best Scientists Citing Alvaro Avezum

Trending Scientists

Recently Published Articles